News
KYKOF
12.84
NaN%
--
Kyowa Kirin downgraded to Sell from Buy at Citi
TipRanks · 03/09 09:35
Kyowa Kirin downgraded to Neutral from Outperform at SMBC Nikko
TipRanks · 03/04 14:10
Kyowa Kirin downgraded to Underweight from Neutral at JPMorgan
TipRanks · 03/03 17:55
Ultragenyx falls as guidance trails consensus amid job cuts
Seeking Alpha · 02/13 19:42
Amgen ends collaboration agreement with Kyowa Kirin for eczema asset
Seeking Alpha · 01/30 19:46
Kyowa Kirin to regain control of rocatinlimab development, commercialization
TipRanks · 01/30 13:21
Kura Oncology rises following Jim Cramer comments
Seeking Alpha · 12/22/2025 17:01
Kyowa Kirin downgraded to Sell from Neutral at Goldman Sachs
TipRanks · 12/16/2025 13:35
Kyowa Kirin announces management changes
Seeking Alpha · 12/11/2025 08:12
Kura Oncology, Kyowa Kirin reveal Komsifti combo data for AML
Seeking Alpha · 12/08/2025 18:00
Kura Oncology wins FDA approval for leukemia drug
Seeking Alpha · 11/13/2025 15:28
Kyowa Kirin reports 9M results
Seeking Alpha · 10/30/2025 16:14
Kyowa Kirin’s Poteligeo Study: A Closer Look at Market Implications
TipRanks · 10/27/2025 21:13
Kyowa Kirin’s New Clinical Trial: A Potential Game-Changer in T-Cell Lymphoma Treatment
TipRanks · 10/27/2025 21:00
Kyowa Kirin’s Promising Study on KHK4951 for Diabetic Macular Edema
TipRanks · 10/27/2025 19:22
Kyowa Kirin’s Promising Phase 2 Study on nAMD Treatment: A Market Game-Changer?
TipRanks · 10/27/2025 18:26
Kyowa Kirin’s KK8123 Study: A Potential Game-Changer for X-linked Hypophosphatemia
TipRanks · 10/27/2025 18:00
Kyowa Kirin’s KK3910: A New Hope in Hypertension Treatment?
TipRanks · 10/27/2025 17:59
Kyowa Kirin’s Phase 3 Trial on KK8398 for Achondroplasia: A Potential Game-Changer
TipRanks · 10/27/2025 17:57
Kyowa Kirin’s Promising Study on KK2845 for Acute Myeloid Leukemia
TipRanks · 10/27/2025 17:18
More
Webull provides a variety of real-time KYKOF stock news. You can receive the latest news about Kyowa Hakko Kogy through multiple platforms. This information may help you make smarter investment decisions.
About KYKOF
Kyowa Kirin Co Ltd is a Japan-based company engaged in the manufacture and sale of medical drugs. The Company operates in Pharmaceuticals business segment. The Company engages in the research, development, manufacture, sale, and import & export of prescription pharmaceuticals. The Company has drug discovery technologies in antibody therapeutics and hematopoietic stem cell gene therapy. Its development pipeline includes AMG531 for aplastic anemia untreated with immunosuppressive therapy, KHK4083/AMG 451 for moderate to severe atopic dermatitis, KHK4083/AMG 451 for moderate to severe asthma, and KK2845 for acute myeloid leukemia and others. In addition, through its subsidiaries, the Company develops, manufactures, markets, and contracts out biosimilar pharmaceuticals, and engages in wholesale and retail sales and insurance agency business. The Company operates in Japan and overseas.